Cargando…
CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia
BACKGROUND: Leukemia stem cells (LSCs) are responsible for the initiation, progression, and relapse of acute myeloid leukemia (AML). Therefore, a therapeutic strategy targeting LSCs is a potential approach to eradicate AML. In this study, we aimed to identify LSC-specific surface markers and uncover...
Autores principales: | Liu, Yongliang, Wang, Guiqin, Zhang, Jiasi, Chen, Xue, Xu, Huailong, Heng, Gang, Chen, Jun, Zhao, Yongchun, Li, Jiatao, Ni, Yuanli, Zhang, Yingzi, Shan, Juanjuan, Qian, Cheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836575/ https://www.ncbi.nlm.nih.gov/pubmed/33494824 http://dx.doi.org/10.1186/s13287-021-02155-6 |
Ejemplares similares
-
Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis
por: Farber, Meike, et al.
Publicado: (2021) -
Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia
por: Boyer, Thomas, et al.
Publicado: (2016) -
Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33
por: Romão, Ema, et al.
Publicado: (2020) -
Transformation of Chronic Myeloid Leukemia to Acute Biphenotypic Leukemia
por: Ivanov, Stanislav, et al.
Publicado: (2020) -
CDK9 inhibitors in acute myeloid leukemia
por: Boffo, Silvia, et al.
Publicado: (2018)